187 related articles for article (PubMed ID: 12447149)
1. Abciximab readministration.
Orford JL; Holmes DR
Rev Cardiovasc Med; 2002; 3(2):67-70. PubMed ID: 12447149
[TBL] [Abstract][Full Text] [Related]
2. Readministration of abciximab: interim report of the ReoPro readministration registry.
Tcheng JE; Kereiakes DJ; Braden GA; Jordan RE; Mascelli MA; Langrall MA; Effron MB
Am Heart J; 1999 Jul; 138(1 Pt 2):S33-8. PubMed ID: 10385789
[TBL] [Abstract][Full Text] [Related]
3. Abciximab readministration: results of the ReoPro Readministration Registry.
Tcheng JE; Kereiakes DJ; Lincoff AM; George BS; Kleiman NS; Sane DC; Cines DB; Jordan RE; Mascelli MA; Langrall MA; Damaraju L; Schantz A; Effron MB; Braden GA
Circulation; 2001 Aug; 104(8):870-5. PubMed ID: 11514371
[TBL] [Abstract][Full Text] [Related]
4. Readministration of abciximab in percutaneous coronary intervention.
Fry ET
J Invasive Cardiol; 1999 Apr; 11(4):251-8. PubMed ID: 10745525
[TBL] [Abstract][Full Text] [Related]
5. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
Nguyen N; Salib H; Mascarenhas DA
J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of abciximab readministration in coronary intervention.
Madan M; Kereiakes DJ; Hermiller JB; Rund MM; Tudor G; Anderson L; McDonald MB; Berkowitz SD; Sketch MH; Phillips HR; Tcheng JE
Am J Cardiol; 2000 Feb; 85(4):435-40. PubMed ID: 10728946
[TBL] [Abstract][Full Text] [Related]
7. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
Kereiakes DJ; Berkowitz SD; Lincoff AM; Tcheng JE; Wolski K; Achenbach R; Melsheimer R; Anderson K; Califf RM; Topol EJ
Am Heart J; 2000 Jul; 140(1):74-80. PubMed ID: 10874266
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
9. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
[TBL] [Abstract][Full Text] [Related]
11. Final results of the ReoPro readministration registry.
Dery JP; Braden GA; Lincoff AM; Kereiakes DJ; Browne K; Little T; George BS; Sane DC; Cines DB; Effron MB; Mascelli MA; Langrall MA; Damaraju L; Barnathan ES; Tcheng JE;
Am J Cardiol; 2004 Apr; 93(8):979-84. PubMed ID: 15081439
[TBL] [Abstract][Full Text] [Related]
12. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
[TBL] [Abstract][Full Text] [Related]
13. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
14. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
[TBL] [Abstract][Full Text] [Related]
15. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
[TBL] [Abstract][Full Text] [Related]
16. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
Dorsch MP; Montague D; Rodgers JE; Patterson C
Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
[TBL] [Abstract][Full Text] [Related]
17. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial.
Gabriel HM; Oliveira JA; da Silva PC; da Costa JM; da Cunha JA
Catheter Cardiovasc Interv; 2006 Aug; 68(2):218-24. PubMed ID: 16817177
[TBL] [Abstract][Full Text] [Related]
18. Delayed immune-mediated thrombocytopenia after re-exposure to abciximab therapy.
Rasti M; Blostein M
Can J Cardiol; 2011; 27(6):869.e13-4. PubMed ID: 21885241
[TBL] [Abstract][Full Text] [Related]
19. Acute severe thrombocytopenia after treatment with ReoPro (abciximab).
Butler R; Hubner PJ
Heart; 2000 Apr; 83(4):E5. PubMed ID: 10722557
[TBL] [Abstract][Full Text] [Related]
20. Acute profound thrombocytopenia following abciximab therapy.
Bishara AI; Hagmeyer KO
Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
